Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11926746rdf:typepubmed:Citationlld:pubmed
pubmed-article:11926746lifeskim:mentionsumls-concept:C0030657lld:lifeskim
pubmed-article:11926746lifeskim:mentionsumls-concept:C0205725lld:lifeskim
pubmed-article:11926746lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:11926746lifeskim:mentionsumls-concept:C0178719lld:lifeskim
pubmed-article:11926746lifeskim:mentionsumls-concept:C0037083lld:lifeskim
pubmed-article:11926746lifeskim:mentionsumls-concept:C0332157lld:lifeskim
pubmed-article:11926746lifeskim:mentionsumls-concept:C0719605lld:lifeskim
pubmed-article:11926746lifeskim:mentionsumls-concept:C1292733lld:lifeskim
pubmed-article:11926746pubmed:dateCreated2002-4-2lld:pubmed
pubmed-article:11926746pubmed:abstractTextPretreatment of human cytomegalovirus (HCMV) with human hyperimmune globulin (CytoGam) in human embryonic lung (HEL) fibroblast culture showed successful inhibition of infectivity, and decreased extracellular viral titers and extracellular viral DNA. CytoGam prevented HCMV from inducing intracellular activation of NF-kappaB, Sp-1, and P13-K signaling pathways and the production of immediate-early (IE), early (E), and late (L) viral proteins. CytoGam neutralization of HCMV in this cell culture model prevented the earliest known signal transduction events (NF-kappaB, Sp-1, P13-K activation) after viral specific glycoproteins bind to their cognate cell membrane receptors, suggesting that this agent contains highly effective neutralizing antibodies against HCMV.lld:pubmed
pubmed-article:11926746pubmed:languageenglld:pubmed
pubmed-article:11926746pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11926746pubmed:citationSubsetIMlld:pubmed
pubmed-article:11926746pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11926746pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11926746pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11926746pubmed:statusMEDLINElld:pubmed
pubmed-article:11926746pubmed:issn1398-2273lld:pubmed
pubmed-article:11926746pubmed:authorpubmed-author:HuangE SESlld:pubmed
pubmed-article:11926746pubmed:authorpubmed-author:HuongS MSMlld:pubmed
pubmed-article:11926746pubmed:authorpubmed-author:WangXXlld:pubmed
pubmed-article:11926746pubmed:authorpubmed-author:AndreoniK AKAlld:pubmed
pubmed-article:11926746pubmed:issnTypePrintlld:pubmed
pubmed-article:11926746pubmed:volume3 Suppl 2lld:pubmed
pubmed-article:11926746pubmed:ownerNLMlld:pubmed
pubmed-article:11926746pubmed:authorsCompleteYlld:pubmed
pubmed-article:11926746pubmed:pagination25-30lld:pubmed
pubmed-article:11926746pubmed:dateRevised2009-10-8lld:pubmed
pubmed-article:11926746pubmed:meshHeadingpubmed-meshheading:11926746...lld:pubmed
pubmed-article:11926746pubmed:meshHeadingpubmed-meshheading:11926746...lld:pubmed
pubmed-article:11926746pubmed:meshHeadingpubmed-meshheading:11926746...lld:pubmed
pubmed-article:11926746pubmed:meshHeadingpubmed-meshheading:11926746...lld:pubmed
pubmed-article:11926746pubmed:meshHeadingpubmed-meshheading:11926746...lld:pubmed
pubmed-article:11926746pubmed:meshHeadingpubmed-meshheading:11926746...lld:pubmed
pubmed-article:11926746pubmed:year2001lld:pubmed
pubmed-article:11926746pubmed:articleTitleHuman CMV-IGIV (CytoGam) neutralizes human cytomegalovirus (HCMV) infectivity and prevents intracellular signal transduction after HCMV exposure.lld:pubmed
pubmed-article:11926746pubmed:affiliationUniversity of North Carolina at Chapel Hill, USA. kenneth_andreoni@med.unc.edulld:pubmed
pubmed-article:11926746pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11926746pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11926746lld:pubmed